Navigation Links
How do anticancer drugs work?
Date:5/3/2013

Wang is the director of the Environmental Toxicology Graduate Program at UC Riverside. He received his bachelor's degree from Shandong University and master's degree from the Chinese Academy of Sciences. He joined the UCR faculty in 2001, after earning his doctoral degree from Washington University in St. Louis.

He is the recipient of the 2013 Biemann Medal and a 2005 Research Award from the American Society for Mass Spectrometry, as well as the inaugural Chemical Research in Toxicology Young Investigator Award from the American Chemical Society in 2012. He was named a Fellow of the American Association for the Advancement of Science in 2012.

Research in the Wang group is concentrated in two broad areas. The first is DNA damage and repair. His lab uses a variety of chemical and biological tools to understand, at the molecular level, how various kinds of damage to DNA are repaired, and how they affect the flow of genetic information during DNA replication and transcription. His work has brought scientists' understanding of the biological consequences of DNA damage to a new level.

His lab's second research area is proteomics, the study of the functions, structures, and interactions of proteins. His work in this area has led to the discovery of novel mechanisms of action of some anti-tumor drugs and environmental toxicants. In particular, he seeks to understand alterations in the expression of proteins in cells that are treated with anticancer drugs and other agents.

Wang's lecture will be introduced by Aurora Johnson, a physical science teacher in the Moreno Valley Unified School District with 11 years of teaching experience. Previously, she worked in the Riverside and Palm Springs Unified School Districts. She was educated at Riverside City College, Grand Cany
'/>"/>

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. 11th International Congress on Targeted Anticancer Therapies
2. Harnessing anticancer drugs for the future fight against influenza
3. High levels of TRAIL protein in breast milk might contribute to anticancer activity
4. Mapping of cancer cell fuel pumps paves the way for new drugs
5. Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes
6. Cholesterol rafts deliver drugs inside cancer cells
7. Findings to help in design of drugs against virus causing childhood illnesses
8. KU Leuven lab coordinates €9m effort to find new deep-sea drugs
9. Mood-modifying drugs for humans also alter fish behavior
10. Study finds potential to match tumors with known cancer drugs
11. £6.5M in funding to help manufacture the drugs of the future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... are leading the largest ever international research project into ... The research will aim to provide new insights into ... kills up to 40,000 women and almost one million ... study, DNA collected from thousands of pregnant women, including ...
... about to be published in EPJ E, French physicists from ... of a thin layer of cells in contact with an ... elastic films. Understanding the mechanism by which a thin layer ... structural integrity, bears great significance because the human tissue, or ...
... TAMPA, Fla. (May 16, 2012) Chlorothalonil, ... on food crops and golf courses, was lethal to ... study, University of South Florida researchers said Wednesday. ... study published in the journal Ecology Letters , ...
Cached Biology News:Nottingham researchers lead world's largest study into pre-eclampsia 2USF study: Common fungicide wreaks havoc on freshwater ecosystems 2
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s ... reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Cup may be two years away, but soccer aficionados ... for global competition when the National Institute of Standards ... second-ever international nanosoccer contest next summer. , Nanosoccerthe Lilliputian ... challenge one another on fields no bigger than a ...
... November 14, 2008 at 9:00 a.m. Eastern ... ... Inc. (Nasdaq: ALSE ) today reports operational and,financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the ...
... Spherix Incorporated,(Nasdaq: SPEX ) reported a net ... 2008 of $1.7 million ($0.12 per share) and $4.8 ... related to the commercialization of Naturlose as a treatment ... nine month period ended,September 30, 2008, compared to approximately ...
Cached Biology Technology:Let the games begin! Nanosoccer at 2009 RoboCup in Austria 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Spherix Reports 3rd Quarter Earnings 2